Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 6/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7969541 | 1.00 | SLC18A3 (0.49) | SLC18A3SIGMAR1ESR1CYP3A4CYP2C9 | |
| SCHEMBL7936686 | 0.90 | SLC18A3 (0.47) | SLC18A3SIGMAR1ESR1CYP3A4CYP2C9 | |
| SCHEMBL26999319 | 0.85 | SLC18A3 (0.56) | SLC18A3SIGMAR1ESR1CYP3A4CYP2C9 | |
| SCHEMBL8029813 | 0.85 | SLC18A3 (0.56) | SLC18A3SIGMAR1ESR1CYP3A4CYP2C9 | |
| SCHEMBL8029809 | 0.85 | SLC18A3 (0.56) | SLC18A3SIGMAR1ESR1CYP3A4CYP2C9 | |
| SCHEMBL715645 | 0.82 | ESR1 (0.53) | ESR1CYP3A4CYP2C9ESR2 | |
| SCHEMBL13718761 | 0.82 | SLC18A3 (0.45) | SLC18A3SIGMAR1AKR1C3AKR1C1 | |
| Ammonia Solution, Strong SCHEMBL2030782 | 0.81 | ESR1 (0.51) | ESR1CYP3A4CYP2C9ESR2 | |
| SCHEMBL5756827 | 0.80 | ESR2 (0.68) | SLC18A3SIGMAR1ESR1CYP3A4CYP2C9 | |
| SCHEMBL10881534 | 0.80 | ESR2 (0.68) | SLC18A3SIGMAR1ESR1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025043225-A2 | DEGRADERS OF CYCLIN-DEPENDENT KINASE 2 | GENENTECH, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| CN-110914238-B | Compounds as antibiotics | 安塔比奥公司 | 2023-06-20 | — | — | CN | disclosed |
| EP-3102198-B1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3102198-B1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10059667-B2 | Antidiabetic compounds | MERCK SHARP & DOHME CORP. (US) | 2018-08-28 | — | — | US | disclosed |
| EP-3102198-A1 | ANTIDIABETIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20160332968-A1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-11-17 | — | — | US | disclosed |
| US-20160332968-A1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-11-17 | — | — | US | disclosed |
| US-20160332968-A1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-11-17 | — | — | US | disclosed |
| WO-2015119899-A1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-08-13 | — | — | WO | disclosed |
| WO-2015119899-A1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-08-13 | — | — | WO | disclosed |
| US-6291520-B1 | INHIBIT THE ENZYME LIPOXYGENASE; TREATMENT OR ALLEVIATION OF INFLAMMATORY DISEASES, ALLERGIC CONDITIONS AND CARDIOVASCULAR DISEASES | PFIZER | 2001-09-18 | — | — | US | disclosed |
| EP-0559743-B1 | NOVEL HYDROXAMIC ACID AND N-HYDROXYUREA DERIVATIVES AND THEIR USE | PFIZER (US) | 1995-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332968-A1 | ANTIDIABETIC COMPOUNDS | GPR119, GLP1R, GIPR | SLC18A3 2395/4885SIGMAR1 2006/4885ESR1 1623/4885 |
| US-10059667-B2 | Antidiabetic compounds | GPR119, GLP1R, GIPR | SLC18A3 2395/4885SIGMAR1 2006/4885ESR1 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.